医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Medidata Expands Partnership with Peking University to Increase Access to Cloud-Based Technology for Clinical Trials Across China

2015年04月07日 AM06:30
このエントリーをはてなブックマークに追加


 

NEW YORK

Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced the expansion of its partnership with Peking University Clinical Research Institute (PUCRI), a world-renowned academic center dedicated to enhancing the development of high-quality clinical research and health innovation in China. Leveraging the research institute’s extensive clinical development network, expertise and resources, the partnership will accelerate the adoption of the Medidata Clinical Cloud® platform across China and, in doing so, optimize local drug development programs by bringing operational efficiencies and greater speed to clinical trials.

“We are delighted to strengthen our partnership with Medidata,” Weigang Fang, vice president of Peking University Health Science Center and director of PUCRI, said. “In China, paper-based clinical trials are still mainstream, especially at Chinese domestic companies. By working with Medidata, we look forward to further advancing clinical development in the country, serving as a bridge between globally-leading technology and innovative drug development.”

Professor Yangfeng Wu, executive associate director of PUCRI, agreed: “The enhanced partnership between PUCRI and Medidata will provide better services and inject new vitality in drug development in China.”

Combining cutting-edge, cloud-based solutions with deep expertise in clinical development, Medidata and PUCRI have collaborated for several years to introduce innovative technology into clinical research in China. Together, they are helping life sciences companies improve operational efficiencies and increase productivity across China’s clinical research programs. In expanding their partnership, Medidata and PUCRI will provide life sciences companies in China with increased accessibility to industry-leading technology that streamlines clinical trials and, ultimately, helps to accelerate the delivery of novel therapies to patients.

Takeru Yamamoto, Medidata’s managing director of the Asia-Pacific region, said, “We are thrilled to be working more closely with PUCRI to bring our globally-recognized cloud-based technology to China. Leveraging PUCRI’s clinical trial expertise will enable us to serve more life sciences organizations in China and to accelerate drug development, allowing patients to access new therapies faster, both from the local market and around the world.”

He added: “We believe that by adopting Medidata’s validated and market-compliant platform, Chinese pharmaceutical companies can more effectively promote placement of their new drugs in overseas markets. And, our enhanced partnership will allow us to increase the number of individuals trained on the Medidata platform—paving the way for the next generation of clinical development leaders.”

About Peking University Clinical Research Institute (PUCRI)

Peking University Clinical Research Institute (PUCRI) was founded in 2008, under the direct leadership of Peking University Health Science Center (PUHSC), as the first university-established public platform specialized in teaching, research, services, training, organizational coordination and technical support of clinical research. Since its inception, PUCRI has successfully built an “academic-enterprise-government” academic exchange platform and model that benefits all three parties. Its partners include government organizations, over 300 hospitals and hundreds of pharmaceutical companies and CROs. PUCRI is committed to improving clinical research in China, so as to promote the development of clinical medicine and people’s well-being. PUCRI provides technical support to various clinical studies including new drug development, specifically research design, execution, quality management, data management and statistical analysis. In 2009, PUCRI and Medidata cofounded “PUCRI Medidata Clinical Research Technology Center.” The Center adopted the global-leading Medidata Rave® electronic data capture and management system and provides high-quality data management technology services to dozens of large multicenter clinical trials.

About Medidata

Medidata is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics. The Medidata Clinical Cloud® brings new levels of productivity and quality to the clinical testing of promising medical treatments, from study design and planning through execution, management and reporting. We are committed to advancing the competitive and scientific goals of global customers, which include over 90% of the top 25 global pharmaceutical companies; innovative biotech, diagnostic and device firms; leading academic medical centers; and contract research organizations.

CONTACT

Investors:
Medidata Solutions
Hulus Alpay, +1
212-419-1025
halpay@mdsol.com
or
Media
– Americas & EMEA:

Medidata Solutions
Nicole
Pariser, +1 212-659-1069
npariser@mdsol.com
or
Media
– APAC:

Medidata Solutions
Masako Ishida, +81 3-4588
0400
mishida@mdsol.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表